Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
New England Journal of Medicine · 07.11.2024 · 391 (18) · 1696-1708
DOI: 10.1056/nejmoa2402604 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 07.11.2024. Verfasst von Christian U Blank und 59 weiteren Autor:innen. Beteiligte Einrichtung: From the Departments of Medical Oncology (C.U.B., M.W.L., L.L.H., J.M.L., S.M.P., J.B.A.G.H., K.A.T.N., J.V.T., S.W., A.M.-E., I.L.M.R.), Pathology (…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Ipilimumab, Melanoma, Neoadjuvant Therapy. Die Arbeit wurde bisher 567-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Bristol-Myers Squibb, Australian Government - National Health and Medical Research Council.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Departments of Medical Oncology (C.U.B., M.W.L., L.L.H., J.M.L., S.M.P., J.B.A.G.H., K.A.T.N., J.V.T., S.W., A.M.-E., I.L.M.R.), Pathology (B.A.W.), Biometrics (M.L.-Y., A.T.A., L.G.G.-O.), Surgical Oncology (W…
ORCID-Profile: Minke W Lucas, Richard A Scolyer, Paolo A Ascierto
Förderung
- Bristol-Myers Squibb
- Australian Government - National Health and Medical Research Council
Zitieren
APA
Blank, C. U., Lucas, M. W., Scolyer, R. A., van de Wiel, B. A., Menzies, A. M., Lopez-Yurda, M., Hoeijmakers, L. L., Saw, R. P. M., Lijnsvelt, J. M., Maher, N. G., Pulleman, S. M., Gonzalez, M., Torres Acosta, A., van Houdt, W. J., Lo, S. N., Kuijpers, A. M. J., Spillane, A., Klop, W. M. C., Pennington, T. E., …, & Hospers, G. A. P. (2024). Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. New England Journal of Medicine, 391(18), 1696-1708. https://doi.org/10.1056/nejmoa2402604
Vancouver
Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. New England Journal of Medicine. 2024;391(18):1696-1708. doi:10.1056/nejmoa2402604
BibTeX
@article{Blank2024,
author = {Blank, Christian U and Lucas, Minke W and Scolyer, Richard A and van de Wiel, Bart A and Menzies, Alexander M and Lopez-Yurda, Marta and Hoeijmakers, Lotte L and Saw, Robyn P M and Lijnsvelt, Judith M and Maher, Nigel G and Pulleman, Saskia M and Gonzalez, Maria and Torres Acosta, Alejandro and van Houdt, Winan J and Lo, Serigne N and Kuijpers, Anke M J and Spillane, Andrew and Klop, W Martin C and Pennington, Thomas E and Zuur, Charlotte L and Shannon, Kerwin F and Seinstra, Beatrijs A and Rawson, Robert V and Haanen, John B A G and Ch'ng, Sydney and Naipal, Kishan A T and Stretch, Jonathan and van Thienen, Johannes V and Rtshiladze, Michael A and Wilgenhof, Sofie and Kapoor, Rony and Meerveld-Eggink, Aafke and Grijpink-Ongering, Lindsay G and van Akkooi, Alexander C J and Reijers, Irene L M and Gyorki, David E and Grünhagen, Dirk J and Speetjens, Frank M and Vliek, Sonja B and Placzke, Joanna and Spain, Lavinia and Stassen, Robert C and Amini-Adle, Mona and Lebbé, Céleste and Faries, Mark B and Robert, Caroline and Ascierto, Paolo A and van Rijn, Rozemarijn and van den Berkmortel, Franchette W P J and Piersma, Djura and van der Westhuizen, Andre and Vreugdenhil, Gerard and Aarts, Maureen J B and Stevense-den Boer, Marion A M and Atkinson, Victoria and Khattak, Muhammad and Andrews, Miles C and van den Eertwegh, Alfons J M and Boers-Sonderen, Marye J and Hospers, Geke A P},
title = {Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma},
journal = {New England Journal of Medicine},
year = {2024},
volume = {391},
number = {18},
pages = {1696--1708},
doi = {10.1056/nejmoa2402604}
}
EUVIMED